Itchy Skin During Pregnancy: Why Scratching Makes It Worse and How to Find Relief

Pruritus during pregnancy—intense, widespread itching without a visible rash—is a common yet often underrecognized symptom that can significantly impact maternal quality of life. While mild itching may result from skin stretching or dryness, persistent, generalized pruritus—especially when worsening with scratching and most pronounced on the palms and soles—warrants prompt clinical evaluation to rule out intrahepatic cholestasis of pregnancy (ICP), a potentially serious obstetric liver disorder.

ICP is characterized by impaired bile acid transport across hepatocytes, leading to elevated serum bile acids—typically exceeding 10 µmol/L—and often accompanied by mild transaminase elevations. It typically emerges in the third trimester, though onset can occur earlier. The hallmark symptom is intense, non-dermatologic pruritus, frequently nocturnal and unrelieved by topical agents or antihistamines. Importantly, ICP carries well-documented fetal risks, including preterm delivery, meconium-stained amniotic fluid, fetal bradycardia, and, in rare cases, stillbirth—necessitating close antenatal surveillance and timely delivery planning.

Diagnosis hinges on measuring fasting serum bile acid concentration and liver enzymes. A bile acid level ≥10 µmol/L confirms ICP; levels ≥40 µmol/L correlate with increased fetal risk. Additional workup should exclude other causes—including drug reactions, viral hepatitis, autoimmune liver disease, and dermatologic conditions such as scabies or atopic eruption of pregnancy.

First-line pharmacologic management is ursodeoxycholic acid (UDCA), administered at 10–15 mg/kg/day in divided doses. UDCA improves maternal pruritus, normalizes liver biochemistry, and may reduce adverse perinatal outcomes. For symptom relief, cool compresses, emollients, and avoidance of hot showers and irritant soaps are recommended. Antihistamines are generally ineffective for ICP-related pruritus and not routinely advised. Close fetal monitoring—including twice-weekly non-stress tests or biophysical profiles—is initiated upon diagnosis, with delivery typically recommended between 36 and 37 weeks’ gestation, depending on bile acid levels and clinical course.

Postpartum, symptoms resolve rapidly—usually within 48 hours—and liver function tests normalize within days to weeks. However, women with prior ICP face an elevated recurrence risk in subsequent pregnancies (up to 60–70%) and a modestly increased long-term risk of developing gallstones or chronic liver disease, warranting ongoing health awareness and periodic hepatic evaluation if symptoms recur outside pregnancy.